Patents by Inventor Oliver QUITT

Oliver QUITT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trispecific binding molecules for treating HBV infection and associated conditions
    Patent number: 10711054
    Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 14, 2020
    Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum fur Gesundheit und umwelt (GmbH), DEUTSCHES KREBSFORSCHUNGSZENTRUM, TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventors: Ulrike Protzer, Felix Bohne, Oliver Quitt, Frank Momburg, Gerhard Moldenhauer
  • TRISPECIFIC BINDING MOLECULES FOR TREATING HBV INFECTION AND ASSOCIATED CONDITIONS
    Publication number: 20180079798
    Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 22, 2018
    Inventors: Ulrike PROTZER, Felix BOHNE, Oliver QUITT, Frank MOMBURG, Gerhard MOLDENHAUER